Evaluation of the efficacy of a food supplement in reducing dry eye symptoms

ISRCTN ISRCTN15920416
DOI https://doi.org/10.1186/ISRCTN15920416
Clinical study protocol NT0000234-25
Sponsor ROELMI HPC SRL (Italy)
Funder ROELMI Srl
Submission date
13/11/2026
Registration date
20/11/2026
Last edited
16/11/2026
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Giovanna Lionetti
Principal investigator

Via Palmiro Togliatti,28H
Cirò Marina (KR)
88811
Italy

Phone +39 (0)3286155993
Email lionettigiovanna@libero.it
Dr Roberta Villa
Public, Scientific

Viale Indipendenza, 11
Pavia
27100
Italy

Phone +39 (0)38225504
Email roberta.villa@complifegroup.com

Study information

Primary study designInterventional
AllocationRandomized controlled trial
MaskingBlinded (masking used)
ControlPlacebo
AssignmentParallel
PurposeTreatment, Efficacy
Scientific titleClinical evaluation of the efficacy of a food supplement in reducing dry eye symptoms: a randomized, double-blind, parallel-group, placebo-controlled study
Study objectives
Ethics approval(s)

Approved 16/05/2025, Independent Ethics Committee for Non-Pharmacological Clinical Investigations (Italian Scientific Society for Non-Pharmacological Clinical Investigations, Via XX Settembre 30/4, Genova, 16121, Italy; +39 (0)10 5454842; a.scudieri@studinonfarmacologici.it), ref: 2025/10

Health condition(s) or problem(s) studiedDry eye
InterventionThe study will be a double-blind, randomized, parallel-group, placebo-controlled clinical study. Half of the subjects will take the active product EXCEPTIONHYAL® WINK containing sodium hyaluronate and half of the subjects will take a placebo for 56 days (T0 to T56). A restricted randomization list will be generated by an independent technician using the appropriate algorithm ("Wei's urn") of the PASS 11 software (PASS, LLC, Kaysville, UT, USA) and stored in a secure location. The principal investigator or his delegate will dispense the products according to the generated randomization list. Subjects will take one capsule a day in the morning, on an empty stomach, with a glass of water.
Intervention typeSupplement
Primary outcome measure(s)
  1. Tear production Schirmer test I measured using the Schirmer test I at T0, T56
  2. Tear film stability measured using the Fluorescein Tear Breakup Time (TBUT) test at T0, T56
  3. Conjunctival hyperemia measured using slit lamp, and the physical sign will be assessed using a 5- point scoring system, where 0 corresponds to no signs, 1 to very mild, 2 to mild, 3 to moderate, and 4 to severe. Conjunctival hyperemia is characterized by increased redness of the eye caused by the dilation of blood vessels in the conjunctiva at T0, T56
  4. Dry eye symptoms and their impact on vision-related function over the past week measured using the Ocular Surface Disease Index (ODSI) at T0, T28, T56
  5. Subjective dry eye symptoms and their impact on daily activities over the past week measured using the Dry Eye-Related Quality-of-Life Score (DEQS) at T0, T28, T56
Key secondary outcome measure(s)
Completion date26/09/2025

Eligibility

Participant type(s)
Age groupAdult
Lower age limit18 Years
Upper age limit64 Years
SexAll
Target sample size at registration66
Total final enrolment66
Key inclusion criteria1. Healthy male and female subjects
2. Caucasian ethnicity
3. Subjects aged between 18 and 64 years (extremes included)
4. Subjects suffering from dry eye discomfort*
5. 34 subjects wear contact lenses, while 32 subjects wear glasses or have normal vision and do not need glasses or contact lenses
6. Subjects registered with National Health Service (NHS)
7. Subjects certifying the truthfulness of the personal data disclosed to the investigator
8. Subjects able to understand the language used in the investigation center and the information given by the investigator
9. Subjects able to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements
10. Commitment not to change the daily routine or the lifestyle
11. Stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least 1 month without any changes expected or planned during the study
12. Subjects informed about the test procedures who have signed a consent form and privacy agreement
*At T0 Ocular Surface Disease Index (ODSI) between 13 and 32 and Dry Eye Questionnaire 5 (DEQ-5) between 6 and
12.
ODSI: is a 12-item questionnaire to assess dry eye symptoms and their impact on vision-related function over the past week. It consists of three subscales: ocular symptoms, vision-related function, and environmental triggers.
Subjects rate each item on a scale from 0 to 4. Based on the total score, symptoms are classified as follows: normal (0–12), mild dry eye (13–22), moderate dry eye (23–32), severe dry eye (33–100).
DEQ-5: is a 5-item questionnaire assessing symptoms experienced in the past month. It evaluates frequency of watery eye, discomfort, and dryness (scored on a 0–4 scale) and intensity of late-day discomfort and dryness (scored on a 0–5 scale). A total score greater than 6 indicates the presence of dry eye, while a score greater than 12 may require further investigation to exclude the possibility of Sjögren's syndrome.
Key exclusion criteria1. Subjects who do not meet the inclusion criteria
2. Subjects wearing glasses with blue light-blocking lenses
3. Subjects with any acute, chronic, or progressive disease or condition that may interfere with the study data or that the investigator considers dangerous to the subject or incompatible with the requirements of the study
4. Subjects participating or planning to participate in other clinical trials
5. Subjects who participated in a similar study without respecting an adequate washout period (at least 1 month)
6. Subjects that have food intolerances or food allergies to ingredients of the study product
7. Subjects under pharmacological treatments that are considered incompatible with the study requirement by the investigator*
8. Subjects who are currently using food supplement(s) and/or topical products (i.e. eye drops) with the same activity as the study product, or who haven't observed an adequate washout period (at least 1 month)**
9. Subjects admitted to a health or social facility
10. Subjects planning a hospitalization during the study
11. Subjects not able to be contacted in case of emergency
12. Subjects deprived of freedom by administrative or legal decision or under guardianship
13. Subjects with a history of drug, alcohol and other substance abuse
14. Subjects with eating disorders (i.e. bulimia, psychogenic eating disorders, etc)
15. Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential)
*Systemic medications that stimulate tear secretion (e.g., pilocarpine, cevimeline)
**Topical ophthalmic medications (corticosteroids, NSAIDs, and cyclosporine); supplements containing omega-3,
vitamin A, vitamin E, lutein, zeaxanthin, and lactoferrin
Date of first enrolment16/05/2025
Date of final enrolment28/05/2025

Locations

Countries of recruitment

  • Italy

Study participating centre

Nutratech SRL
Via Francesco Todaro 20/22
Rende
87036
Italy

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

16/11/2026: Study's existence confirmed by the Independent Ethics Committee for Non-Pharmacological Clinical Investigations.